Skip to main content
. Author manuscript; available in PMC: 2016 May 2.
Published in final edited form as: J Neurotrauma. 2011 Dec 20;29(3):539–550. doi: 10.1089/neu.2011.1976

FIG. 4.

FIG. 4

CD11d monoclonal antibody (mAb) treatment decreases inflammation and oxidative damage in the injured spinal cord. (A) Myeloperoxidase (MPO) activity was measured in cord homogenates. CD11d mAb (gray bars) treatment significantly reduced MPO activity at 24 h, 3 days, and 7 days post-injury compared to controls (1B7, open bars). (B) Malondialdehyde (MDA), a measure of lipid peroxidation, was significantly reduced in cord homogenates by the anti-CD11d treatment (gray bars) compared to control treatment (1B7, open bars) at 24 h and 3 days post-injury. (C) 2′-7′-Dichlorofluorescin diacetate (DCFH-DA) oxidation, a measure of reactive oxygen species in injured cord, was significantly reduced by CD11d mAb treatment (gray bars) compared to control treatment (1B7, open bars). Values are means ± standard error (*p<0.05 significantly different from controls by Student’s t-test; n=4 at 24 h; n=6 at 3 days; n=4 at 7 days; n=6 at 2 weeks).